Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
07:00am, Thursday, 31'st Jul 2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage i
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel s
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
11:48pm, Friday, 04'th Jul 2025
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see sign
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
09:20am, Friday, 04'th Jul 2025
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial
12:56pm, Monday, 30'th Jun 2025
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
11:52am, Monday, 30'th Jun 2025
INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro.
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
07:36am, Monday, 30'th Jun 2025
INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plu
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease
07:30am, Monday, 30'th Jun 2025
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary
INmune Bio: Finding Pay Dirt In Alzheimer's?
04:50pm, Friday, 27'th Jun 2025
INmune Bio is working on a drug for Alzheimer's, with a critical phase 2 readout to be announced. It is unclear whether this will be positive or negative. Other potential drug candidates could help pi
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12:16pm, Friday, 27'th Jun 2025
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered int
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes
10:38am, Friday, 27'th Jun 2025
INmune Bio Inc. INMB stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, per data from Benzinga Pro.
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th
04:00pm, Thursday, 26'th Jun 2025
Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clini
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
11:29am, Monday, 16'th Jun 2025
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mec
